Phase 3 Psoriasis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Young people aged 12 to under 18 years old (Group 1), or children aged 4 to under 12 years old (Group 2), of any gender
- Have been diagnosed with plaque psoriasis for at least 6 months
- Have a moderate to severe level of psoriasis
- Have been considered a suitable candidate for light therapy or medication that works throughout the body
- For the long-term extension part of the trial only: must have already completed the full 52-week treatment period in an earlier part of this study
Who may not be able to join:
- Young people aged 12 to under 18 who weigh 30 kg (about 66 lbs) or less at the time of screening, or children aged 4 to under 12 who weigh less than 18 kg (about 40 lbs) at screening
- People who have a type of psoriasis other than plaque psoriasis
- People who have had a recent infection (confirm with trial site for exact timeframe)
- People who have previously taken the study drug deucravacitinib or a similar comparison medication used in this trial
- People who show signs of active tuberculosis (TB) — this applies to the long-term extension part of the trial
- There may be additional requirements not listed here (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Phone: 855-907-3286
Australian sites
+409121547
30681111
+61730391311
0395936666
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
6 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Observed average concentration at steady state for deucravacitinib at Week 2; Maximum observed plasma concentration at steady state for deucravacitinib at Week 2; Trough observed plasma concentration for deucravacitinib at Week 2; Proportion of subjects with at least 75% improvement in Psoriasis Area and Severity Index (PASI 75) at Week 16; Proportion of subjects with an static Physician's Global Assessment (sPGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point reduction from baseline at Week 16; Incidence of Adverse Events (AEs); Incidence of serious adverse events (SAEs); Moni...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.